MedWatch

UCPH spin-out to develop the future's obesity medicine with Novo Nordisk

Less than a year after Embark Biotech was spun out from University of Copenhagen, the new Danish biotech company has entered a comprehensive collaboration with Novo Nordisk to develop a brand new class of obesity drugs.

Embark Biotech is based in Cobis Science Park | Foto: Jan Bjarke Mindegaard

Last year, Danish drug group Novo Nordisk set a strategy that involved bringing in more external innovation to the company. This year, the firm has already been in Germany, England and especially the US to find new partners.

However, the company is also looking for external innovation closer to home and has now entered a collaboration with the young Danish company Embark Biotech.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier